February 12, 2005
Pharmacosmos has received the official accept from the US Food & Drug Administration (FDA) for the manufacturing of dextran and iron dextran compounds.
About Pharmacosmos A/S
Pharmacosmos develops and markets
medicines for the treatment of iron deficiency. A research-based
company, its ongoing R&D programme focuses on improving the
treatment options for healthcare professionals and patients
suffering from iron deficiency.
Pharmacosmos is a privately-owned
company and operates in more than 50 countries across Europe, the
Americas and Asia. All its manufacturing is approved by the Danish
Medicines Agency and the US Food & Drug Administration.